Globus Medical, Inc. (GMED)

$51.44

+0.17

(+0.33%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Globus Medical, Inc.

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 254.14M → 616.53M (in $), with an average increase of 15.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 998.0K → 15.03M (in $), with an average increase of 93.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 34.4% return, outperforming this stock by 46.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 61.5% return, outperforming this stock by 89.4%

Performance

  • $51.08
    $51.97
    $51.44
    downward going graph

    0.7%

    Downside

    Day's Volatility :1.71%

    Upside

    1.02%

    downward going graph
  • $43.39
    $62.88
    $51.44
    downward going graph

    15.65%

    Downside

    52 Weeks Volatility :31.0%

    Upside

    18.19%

    downward going graph

Returns

PeriodGlobus Medical, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-5.04%
1.9%
0.0%
6 Months
4.02%
10.7%
0.0%
1 Year
-11.74%
4.6%
-1.1%
3 Years
-28.29%
14.2%
-22.1%

Highlights

Market Capitalization
6.9B
Book Value
$29.32
Earnings Per Share (EPS)
1.07
PE Ratio
47.9
PEG Ratio
1.75
Wall Street Target Price
61.46
Profit Margin
7.83%
Operating Margin TTM
12.74%
Return On Assets TTM
4.77%
Return On Equity TTM
4.21%
Revenue TTM
1.6B
Revenue Per Share TTM
13.87
Quarterly Revenue Growth YOY
124.6%
Gross Profit TTM
759.1M
EBITDA
418.2M
Diluted Eps TTM
1.07
Quarterly Earnings Growth YOY
-0.79
EPS Estimate Current Year
2.69
EPS Estimate Next Year
3.29
EPS Estimate Current Quarter
0.61
EPS Estimate Next Quarter
0.6

Analyst Recommendation

Buy
    50%Buy
    45%Hold
    4%Sell
Based on 22 Wall street analysts offering stock ratings for Globus Medical, Inc.(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
10
9
Hold
10
10
11
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 19.48%

Current $51.44
Target $61.46

Company Financials

FY18Y/Y Change
Revenue
713.0M
↑ 12.11%
Net Income
156.5M
↑ 45.76%
Net Profit Margin
21.95%
↑ 5.07%
FY19Y/Y Change
Revenue
785.4M
↑ 10.15%
Net Income
155.2M
↓ 0.81%
Net Profit Margin
19.76%
↓ 2.19%
FY20Y/Y Change
Revenue
789.0M
↑ 0.47%
Net Income
102.3M
↓ 34.1%
Net Profit Margin
12.96%
↓ 6.8%
FY21Y/Y Change
Revenue
958.1M
↑ 21.43%
Net Income
149.2M
↑ 45.86%
Net Profit Margin
15.57%
↑ 2.61%
FY22Y/Y Change
Revenue
1.0B
↑ 6.76%
Net Income
190.2M
↑ 27.47%
Net Profit Margin
18.59%
↑ 3.02%
FY23Y/Y Change
Revenue
1.6B
↑ 53.34%
Net Income
122.9M
↓ 35.39%
Net Profit Margin
7.83%
↓ 10.76%
Q3 FY22Q/Q Change
Revenue
254.1M
↓ 3.6%
Net Income
47.4M
↓ 13.11%
Net Profit Margin
18.66%
↓ 2.05%
Q4 FY22Q/Q Change
Revenue
274.5M
↑ 8.01%
Net Income
50.1M
↑ 5.55%
Net Profit Margin
18.24%
↓ 0.42%
Q1 FY23Q/Q Change
Revenue
276.7M
↑ 0.8%
Net Income
49.1M
↓ 1.87%
Net Profit Margin
17.76%
↓ 0.48%
Q2 FY23Q/Q Change
Revenue
291.6M
↑ 5.39%
Net Income
57.7M
↑ 17.47%
Net Profit Margin
19.79%
↑ 2.03%
Q3 FY23Q/Q Change
Revenue
383.6M
↑ 31.56%
Net Income
998.0K
↓ 98.27%
Net Profit Margin
0.26%
↓ 19.53%
Q4 FY23Q/Q Change
Revenue
616.5M
↑ 60.71%
Net Income
15.0M
↑ 1406.41%
Net Profit Margin
2.44%
↑ 2.18%
FY18Y/Y Change
Total Assets
1.3B
↑ 20.6%
Total Liabilities
115.2M
↑ 4.0%
FY19Y/Y Change
Total Assets
1.5B
↑ 17.79%
Total Liabilities
129.6M
↑ 12.57%
FY20Y/Y Change
Total Assets
1.7B
↑ 9.62%
Total Liabilities
173.2M
↑ 33.61%
FY21Y/Y Change
Total Assets
2.0B
↑ 16.54%
Total Liabilities
215.9M
↑ 24.65%
FY22Y/Y Change
Total Assets
2.1B
↑ 6.07%
Total Liabilities
229.8M
↑ 6.43%
FY23Y/Y Change
Total Assets
5.1B
↑ 144.98%
Total Liabilities
1.1B
↑ 373.61%
Q3 FY22Q/Q Change
Total Assets
2.0B
↑ 3.23%
Total Liabilities
212.4M
↓ 1.49%
Q4 FY22Q/Q Change
Total Assets
2.1B
↑ 5.04%
Total Liabilities
229.8M
↑ 8.17%
Q1 FY23Q/Q Change
Total Assets
2.1B
↑ 3.54%
Total Liabilities
234.8M
↑ 2.2%
Q2 FY23Q/Q Change
Total Assets
2.2B
↑ 2.92%
Total Liabilities
227.4M
↓ 3.15%
Q3 FY23Q/Q Change
Total Assets
5.4B
↑ 142.08%
Total Liabilities
1.2B
↑ 413.89%
Q4 FY23Q/Q Change
Total Assets
5.1B
↓ 5.04%
Total Liabilities
1.1B
↓ 6.89%
FY18Y/Y Change
Operating Cash Flow
181.6M
↑ 13.86%
Investing Cash Flow
-193.0M
↑ 73.47%
Financing Cash Flow
32.6M
↑ 1903.08%
FY19Y/Y Change
Operating Cash Flow
172.0M
↓ 5.32%
Investing Cash Flow
-140.3M
↓ 27.33%
Financing Cash Flow
24.4M
↓ 24.96%
FY20Y/Y Change
Operating Cash Flow
198.8M
↑ 15.59%
Investing Cash Flow
-117.3M
↓ 16.37%
Financing Cash Flow
-38.7M
↓ 258.2%
FY21Y/Y Change
Operating Cash Flow
276.3M
↑ 38.98%
Investing Cash Flow
-375.9M
↑ 220.43%
Financing Cash Flow
54.1M
↓ 240.05%
FY22Y/Y Change
Operating Cash Flow
178.5M
↓ 35.4%
Investing Cash Flow
-110.4M
↓ 70.64%
Financing Cash Flow
-110.0M
↓ 303.08%
Q3 FY22Q/Q Change
Operating Cash Flow
32.9M
↓ 10.74%
Investing Cash Flow
-63.1M
↓ 332.66%
Financing Cash Flow
13.2M
↓ 109.22%
Q4 FY22Q/Q Change
Operating Cash Flow
64.0M
↑ 94.33%
Investing Cash Flow
-60.5M
↓ 4.16%
Financing Cash Flow
13.6M
↑ 3.26%
Q1 FY23Q/Q Change
Operating Cash Flow
53.3M
↓ 16.67%
Investing Cash Flow
11.0M
↓ 118.17%
Financing Cash Flow
2.9M
↓ 78.37%
Q2 FY23Q/Q Change
Operating Cash Flow
35.0M
↓ 34.3%
Investing Cash Flow
52.2M
↑ 375.09%
Financing Cash Flow
1.1M
↓ 63.13%
Q3 FY23Q/Q Change
Operating Cash Flow
50.5M
↑ 44.12%
Investing Cash Flow
-80.9M
↓ 254.84%
Financing Cash Flow
1.4M
↑ 31.46%

Technicals Summary

Sell

Neutral

Buy

Globus Medical, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Globus Medical, Inc.
Globus Medical, Inc.
0.23%
4.02%
-11.74%
-28.29%
11.94%
Stryker Corporation
Stryker Corporation
-4.59%
26.35%
10.88%
26.25%
80.99%
Boston Scientific Corp.
Boston Scientific Corp.
2.53%
35.38%
34.38%
63.21%
94.67%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-5.81%
24.49%
-1.17%
-8.62%
48.12%
Abbott Laboratories
Abbott Laboratories
-2.2%
13.48%
-2.55%
-12.23%
40.18%
Medtronic Plc
Medtronic Plc
-2.34%
12.97%
-9.37%
-37.53%
-5.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Globus Medical, Inc.
Globus Medical, Inc.
47.9
47.9
1.75
2.69
0.04
0.05
NA
29.32
Stryker Corporation
Stryker Corporation
39.67
39.67
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.57
63.57
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.15
38.15
5.19
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.36
33.36
5.99
4.61
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.58
25.58
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Globus Medical, Inc.
Globus Medical, Inc.
Buy
$6.9B
11.94%
47.9
7.83%
Stryker Corporation
Stryker Corporation
Buy
$124.7B
80.99%
39.67
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.0B
94.67%
63.57
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.8B
48.12%
38.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$185.8B
40.18%
33.36
13.96%
Medtronic Plc
Medtronic Plc
Buy
$107.0B
-5.08%
25.58
13.0%

Institutional Holdings

  • Vanguard Group Inc

    8.33%

  • BlackRock Inc

    8.01%

  • HHG PLC

    5.84%

  • State Street Corporation

    2.61%

  • Wellington Management Company LLP

    2.15%

  • Bank of New York Mellon Corp

    2.15%

Company Information

globus medical, inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. founded in 2003, globus’ single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders. additional information can be accessed at www.globusmedical.com.

Organization
Globus Medical, Inc.
Employees
5000
CEO
Mr. David C. Paul
Industry
Health Technology

Discover More

FAQs